Abstract:
The invention provides means and methods for stem cell proliferation and subsequent generation and expansion of progenitor cells. The invention in particular provides media and other culture conditions for the same. The cells are preferably used as effector cells as clinical therapeutics.

Description:
[0001]    The invention relates to the field of modern medical biology. In particular the invention relates to stem cell technology. More in particular the invention relates to perinatal stem cell technology, in particular umbilical cord stem cell technology. 
         [0002]    Stem cells are primal undifferentiated cells which have the ability for self-renewal and the ability to differentiate into other cell types. This ability allows them to act as a repair system for the body, replenishing other cells as long as the organism is alive. 
         [0003]    Stem cells are categorized by potency which describes the specificity of that cell. 
         [0004]    Totipotent stem cells are cells that have the ability of self renewal and are capable of differentiating into any and all cell type to form an entire new organism. They are typically produced from the fusion of an egg and sperm cell. Cells produced by the first few divisions of the fertilized egg cell are also totipotent. These cells can grow into any cell type without exception. 
         [0005]    Pluripotent stem cells are the descendants of totipotent cells and can grow into any cell type except for totipotent stem cells. 
         [0006]    Multipotent stem cells can produce only cells of a closely related family of cells (e.g. hematopoietic stem cells can differentiate into blood cells such as red blood cells, white blood cells and platelets). 
         [0007]    Progenitor (sometimes called unipotent) cells can produce only one cell type; but, have the property of self-renewal which distinguishes them from non-stem cells. 
         [0008]    Stem cells are also categorized according to their source, as either adult or embryonic. 
         [0009]    Adult stem cells are undifferentiated cells found among differentiated cells of a specific tissue and are mostly multipotent cells. They are more accurately called somatic stem cells, because they need not come from adults but can also come from children or umbilical cords. 
         [0010]    Embryonic stem cells are cells obtained from the undifferentiated inner mass cells of a blastocyst, an early stage embryo that is 50 to 150 cells. 
         [0011]    Blood from the the placenta and umbilical cord that are left over after birth is one source of adult stem cells. It is collected by removing the umbilical cord, cleansing it and withdrawing blood from the umbilical vein. 
         [0012]    Red blood cells can be removed from the cord blood and the remaining cells can be used or stored (e.g. in liquid nitrogen). 
         [0013]    Stem cells themselves are useful in many applications of so-called regenerative medicine. They have been used to treat heart disease, repair spinal chords and many other diseases where tissues of all kinds needed to be replaced. 
         [0014]    Stem cells can also be used to produce certain kinds of differentiated cells that are effector cells in certain diseases. 
         [0015]    Unfortunately however, stem cells are present in the body of a mammal in minute quantities only. Often they are present in organs or tissues that can not easily be reached. Embryonic stem cell are also not easily obtainable and only in minute quantities. Moreover, there are some ethical concerns in growing embryos merely for the purpose of producing stem cells. There is a need therefore for methods for multiplying available stem cells and/or primitive lineage specific progeny thereof, without differentiating into less potent descendants. Totipotent stem cells should remain totipotent after expansion and not turn into pluripotent stem cells, pluripotent stem cells should remain pluripotent, etc. In some instances the change into a less potent descendant may be acceptable (at least to a certain extent) as long as the potential for self renewal and at least multipotency is retained. 
         [0016]    Although stem cells have the ability of self-renewal, maintaining stem cells in culture, is not an easy task. In its broadest sense the present invention provides a medium and a method for stem cell culture and/or expansion and/or differentiation comprising a number of elements that are extremely suitable for just that purpose. 
         [0017]    Thus in one embodiment the invention provides a medium for culturing, expanding and/or differentiating stem cells, said medium comprising a basic cell culture medium, 1-20% human serum, 2-10 mmol/l O-acetyl-L-carnitine or a functional equivalent thereof, 40-80 mg/l N-desulphated-N-acetylated heparin or a functional equivalent thereof and a combination of suitable cytokines, preferably encompassing three or more of thrombopoietin, flt-3 ligand, stem cell factor, G-CSF, GM-CSF, IL-6, MIP-I-α, and LIF, and further conventional supplements, such as L-glutamine, antibiotics, ascorbic acid, selenium selenite and ethanolamine. The cytokines given are chosen for their functions. For some of the cytokines given there are other cytokines which will at least in part be able to perform the same function. Those can then of course substitute the listed ones. 
         [0018]    Preferably a medium according to the invention comprises about 3-8, more preferably about 5 mmol/l of O-acetyl-L-carnitine. A functional equivalent may be present in different amounts which are equivalent in activity to the amounts given for O-acetyl-L-carnitine. 
         [0019]    Preferably a medium according to the invention comprises about 50-70, more preferably about 60 mg/l of N-desulphated-N-acetylated heparin. A functional equivalent may be present in different amounts which are equivalent in activity to the amounts given for N-desulphated-N-acetylated heparin. 
         [0020]    The amounts of cytokine added are conventional in the art, preferred amounts are given in the examples, but 10% deviations in amount are very well acceptabler and within the scope of the present invention. 
         [0021]    Many basic media are known. A selection is given below, but many more may be bought from companies such as invitrogen. Basic media include but are not limited to BEM (Basic Eagle Medium), DMEM (Dulbecco&#39;s modified Eagle Medium), Glasgow minimal essential medium, M199 basal medium, HAM F10, HAM F12, Iscove&#39;s DMEM, Leibovitz L15, MCDB, McCoy 5A, etc. 
         [0022]    Combinations of these basic media can also be used and combinations of DMEM and HAM F12 are preferred for some differentiation media according to the invention. The amounts given herein are typically suitable for cultures which are started with about 1 million cells per ml. The amounts may be adapted for different amounts of cells with which cultures are started. 
         [0023]    The media according to the invention can be varied in their serum content, preferably together with a different combination of cytokines to provide either an expansion medium or a differentiation medium. 
         [0024]    Thus, in one embodiment of the present invention a medium and a method for proliferating stem cells with subsequent generation of primitive lineage specified progenitor cells, particularly stem cells from cord blood, is provided in a form that stem cell proliferation produces one daughter stem cell and one primitive progenitor stem cell, the latter with the ability of extensive self-renewal and functional maturation. Typically from 1 million cells of a stem cell enriched population 1×10 8  primitive progenitors can be generated while maintaining the stem cell pool. Each primitive progenitor is capable to produce &gt;1×10 3  functional maturated effector cells. The stem cell enriched population may be isolated CD34+ cells and/or CD133+cells. The addition of monocyte enriched CD14+ cells enhances the amplification as well as maturation of the desired cells. 
         [0025]    The present invention in said embodiment provides a medium for expanding stem cells comprising a basic cell culture medium, 10-20% human serum, 2-10 mmol/l O-acetyl-L-carnitine or a functional equivalent thereof, 40-80 mg/l N-desulphated-N-acetylated heparin or a functional equivalent thereof and a combination of suitable cytokines, preferably encompassing three or more of thrombopoietin, flt-3 ligand, stem cell factor, G-CSF, GM-CSF, IL-6, MIP-I-α, and LIF, and further conventional supplements, such as L-glutamine, antibiotics, ascorbic acid, selenium selenite and ethanolamine. 
         [0026]    Preferably, a medium for expansion according to the invention comprises about 15% of human serum, preferably AB serum. Preferably a medium for expansion according to the invention comprises about 5 mmol/l O-acetyl-L-carnitine. Preferably a medium for expansion according to the invention comprises 60 mg/l N-desulphated-N-acetylated heparin. The preferred basic medium is RPMI1640. 
         [0027]    In a further preferred embodiment a medium for expansion according to the invention comprises thrombopoietin, flt-3 ligand, stem cell factor, G-CSF, GM-CSF, IL-6, MIP-I-α, LIF, VEGF, bFGF, IL-3 and IL-7 in conventional amounts, preferably in the amounts given in the examples. 
         [0028]    In another embodiment the invention provides differentiation media for differentiation into Natural Killer cell progenitors, preferably two media for two steps in differentiation, for which media the amount of human serum lies between 5-10%. Preferably the amount of serum is around 8%. Preferably a medium for differentiation according to the invention comprises about 5 mmol/l O-acetyl-L-carnitine. Preferably a medium for differentiation according to the invention comprises 60 mg/l N-desulphated-N-acetylated heparin. The preferred basic medium is a mixture of 2:1 (v/v) DMEM and HAM-F12. 
         [0029]    A preferred combination of cytokines for the first step in differentiation is TPO, FLT-3L, SCF, IL-7, VEGF, IL-2, GM-CSF, G-CSF, LIF, MIP-I-α and IL-6. This medium is preferably applied after expansion of stem cells for about three days, preferably expansion in an expansion medium according to the invention. 
         [0030]    Preferably this first differentiation step into natural killer cell progenitors is followed by a further differentiation step about three days later (at 6 days since harvest or thawing) with yet a different secondary differentiation medium according to the invention in which the cells should be cultured for about 9-24, preferably 12-22 days). 
         [0031]    A second differentiation medium according to the invention comprises 5-10% human serum (preferably AB), preferably about 8% human serum. 
         [0032]    Preferably a second medium for differentiation according to the invention comprises about 5 mmol/l O-acetyl-L-carnitine. Preferably a second medium for differentiation according to the invention comprises 60 mg/l N-desulphated-N-acetylated heparin. The preferred basic medium is a mixture of 2:1 (v/v) DMEM and HAM-F12. A preferred combination of cytokines for the second step in differentiation is TPO, FLT-3, SCF, IL-7, IL-15, IL-2, GM-CSF, G-CSF, LIF, IL-6, MIP-I-α. 
         [0033]    This medium should be refreshed between 3-8, preferably around 6 days. 
         [0034]    The invention also encompasses methods for maintaining while proliferating stem cells with the generation and expansion of progenitor cells, in particular stem cells from umbilical cord blood, comprising harvesting stem cells from cord blood, culturing said cells in a medium according to the invention and separating the expanded cells from said medium. The invention further comprises methods for differentiating stem cells into NK progenitor cells comprising culturing said stem cells, in particular stem cells derived from umbilical cord blood, in a differentiation medium according to the invention and preferably culturing said stem cells in a first and a second differentiation medium in a scheme as given in the detailed description below. Culturing must occur under conventional suitable conditions typically encompassing temperatures of around 37 degrees Celsius, 100%RH, 10%O2 and 5-7%CO2. 
         [0035]    The invention also encompasses proliferated and maintained stem cells produced by a process according to the invention. 
         [0036]    The invention also encompasses natural killer progenitor cells produced by a method according to the invention. 
         [0037]    In a further embodiment the invention comprises a set of media (kit of parts) for proliferation and maintenance of stem cells, in particular derived from cord blood) and generation of primitive NK progenitor cells, comprising an expansion medium according to the invention, a first and a second deifferentiation medium according to the invention and preferably an instruction leaflet for use of the media. 
         [0038]    The NK progenitor cells can be differentiated into mature and functional NK cells recognizing a desired target by specific receptors on their surface known to the expert in the field (CD56, CD16, CD107, NKG2a/CD94, NKp-antigens, KIR-receptors). These mature and functional NK cells can be generated in vitro by extending the culture period 2-3 more weeks. However, as cellular therapeutic the injection of the primitive progenitors and maturation in vivo is preferred. These NK cells can be used in the treatment of any kind of human disease preferably all malignant diseases such as tumors, cancer, in particular leukemias, ovarian, colon and skin cancers, Breast, Brain and Lung cancers, Cervical cancer and metastases of all kinds of cancer, particularly to the liver, as well as all viral diseases, in particular HIV, HCV, and other chronic viral diseases Methods for (expanding and) differentiating stem cells into NK progenitor cells and onward into NK cells are also part of the present invention. 
         [0039]    The target specific NK cells produced by these methods are also part of the present invention. Pharmaceutical compositions comprising progenitor cells or mature NK cells produced according to the invention and further comprising usual constituents of such compositions are also part of the present invention. Doses for such pharmaceutical compositions are generally expressed in the number of viable cells present in such a composition. Said number should be between 1-9×10 6  NK-IC or &gt;1-10×10 8  mature NK-cells per kg body weight of a subject to be treated. 
         [0040]    In another embodiment the invention comprises a medium for differentiating (expanded) stem cells into Vascular progenitor cells. 
         [0041]    In this embodiment a preferred (first) differentiation medium comprises a basic medium (preferably M199 basal medium) with about 7-12, preferably about 10% human serum preferably AB), about 4-6, preferably about 5 mmol/l of O-acetyl-L-carnitine, about 60 mg/l N-desulphated-N-acetylated heparin. 
         [0042]    The following combination of cytokines is preferred: SCGF, VEGF, Angiopoietin-1, angiopoietin-2, bFGF, IGF, TPO, FLT-3L, Il-1β, GM-CSF, G-CSF, LIF, MIP-I-α and 11-6. The amounts again are preferably those given in the examples, although 10% deviations will typically be acceptable. Other usual constituents for culture media as given herein before may of course be added. 
         [0043]    It is preferred to further enhance the differentiation into VP cells by culturing the cells in a second differentiation medium. The scheme preferred is given in the detailed description, although such a scheme is not critical. The lengths of the different culture steps can be varied. 
         [0044]    This second culture medium mainly differs from the first in the amount of human serum present, which should be about 1-4%, preferably around 2%. 
         [0045]    The preferred set of cytokines is SCGF, VEGF, bFGF, IGF, TPO, FLT-3L and IL-1β. 
         [0046]    The invention also encompasses vascular progenitor cells produced by a method according to the invention. These cells can be used for treatment of any cardiovascular disease involving the generation of newe blood vessels or new endothelium. Pharmaceutical compositions comprising vascular progenitor cells are also part of the present invention. The amount of cells per dose will typically comprise at least 1×10 6  viable cells per dose. 
         [0047]    In a further embodiment the invention comprises a set of media (kit of parts) for expansion and differentiation of stem cells, in particular derived from cord blood) into vascular progenitor cells, comprising an expansion medium according to the invention, a first and a second differentiation medium according to the invention and preferably an instruction leaflet for use of the media. 
         [0048]    Methods for differentiating stem cells into vascular progenitor cells and onward into functional new endothelium and blood vessels leading to revascularisation of the tissue are also part of the present invention. 
         [0049]    The invention will be explained in more detail in the following detailed description. 
     
    
     DETAILED DESCRIPTION  
       [0050]    The following description discloses a method of in vitro generation of cellular therapeutics for clinical use that can be derived from small aliquots of postembryonic stem cells. This procedure is characterized by culturing postembryonic stem cells in a specifically formulated medium with a defined composition as well as a defined culture handling procedure to yield sufficient progenitors for clinical application. 
         [0051]    The invention disclosed in here is at least in part based on the technical problem that for the treatment of malignant diseases, i.e. cancer, leukaemias and lymphomas as well as for cardiovascular diseases the availability of cellular therapies is very limited. With the exception of very few haematopoietic stem cell transplantations using umbilical cord blood (UCB), postembryonic stem cells have not been used for targeted cellular treatment in a non-allogeneic transplant setting without high dose chemotherapy/radiation-conditioning of the patient mainly due to the fact, that sufficient directed progenitor cells for cellular therapy are not available yet. In addition, these cells are alloreactive and cause severe graft-versus host disease in the recipient if treatment and cellular product are not optimal chosen. The technical problem was at least partly solved in this invention by providing practicable procedures to generate sufficient numbers of progenitors for selected treatments as indicated herein before. The technical problem of selected progenitor generation of human postembryonic stem cells for clinical application could be solved by applying both well defined procedures of in vitro culture steps as well as specific changes of the culture conditions as described in the method section. These procedures allow for the first time the production of vascular progenitors (VP-cells) and/or Natural-Killer-cell (NK-cell)-progenitors for clinical application from small postembryonic stem cell aliquots. 
         [0052]    The following postembryonic stem cells that can be obtained beginning from week 12 after gestation from foetal liver, perinatal umbilical cord blood (UCB), human bone marrow or G-CSF stimulated peripheral blood can be isolated and used for cultivation procedures according to the invention. The person skilled in the art knows methods for the collection of these stem cells, whereby the harvest from perinatal umbilical cord or placental blood is preferred for the procedures according to the invention. 
         [0053]    In a further preferred embodiment of the procedures according to the invention a functional proof of the final cellular therapeutic is performed consecutive to cultivation. Especially preferred is the proof of progenitor features of Natural Killer Cells (NK-cells) as well as vascular progenitor cells (VP-cells) by established in vitro assay systems. 
       The Following Example Illustrates the Invention: 
     1. Initiation of the In Vitro Culture: 
       [0054]    Small aliquots of postembryonic stem cells (minimum 25 ml of human umbilical cord blood; an amount that is well below the required minimum amount for clinical banking) are processed according standard operating procedures of red cell lysis to obtain nucleated cells for further processing. As a option cells can be further purified by immunomagnetic cell separation according to the manufacturer (Miltenyi-Biotec, Germany) into enriched CD34+ cells (or alternatively CD133+ cells) and additionally CD14+ cells can be separated as well. The person of skill in this field will be able to perform these cell separations according to the manufacturer. These cells are put in culture flasks or Teflon bags that contain the so called  G lycostem- T echnology- I nitiation or GTI-medium: The medium in this example consists of RPMI1640 (Invitrogen Inc.) containing 15% human AB-serum (Cambrex Inc.), O-acetyl-L-carnitine (OALC, Sigma Chemicals) or derivatives in a final concentration of 5 mmol/l, N-desulfated-N-acetylated heparin (Seigagaku Amerika Inc.) in a concentration of 60 mg/l. The following recombinant human cytokines (if not specifically mentioned all cytokines have been provided by Stem Cell Technology Inc. or R&amp;D Systems): thrombopoietin (TPO; 25 ng/ml); flt-3Ligand (FLT-3L; 25 ng/ml), stem cell factor (SCF; 25 ng/ml), interleukin-7 (IL-7; 25 ng/ml), vascular endothelial growth factor (VEGF; 10 ng/ml), interleukin-3 (IL-3; 2,5 ng/ml), basic fibroblast growth factor (bFGF; 10 ng/ml), insulin like growth factor (IGF; 10 ng/ml), granulocyte-macrophage-colony-stimulating factor (GM-CSF; 10 pg/ml Immunex Corp., Seattle, Wash.), granulocyte-colony-stimulating factor (G-CSF, 250 pg/ml; Amgen, Thousand Oaks, Calif.), Leukemia-inhibitory factor (LIF; 50 pg/ml), Macrophage-inflammatory protein-1alpha (200 pg/ml; MIP-I alpha) and interleukin-6 (IL-6; 50 pg/ml). Additional supplements are L-glutamine (2 mmol/l; Invitrogen), penicillin (1000 U/ml), streptomycin 100 U/ml (Invitrogen), 25 μM 2-mercaptoethanol-beta (Invitrogen) ascorbic acid (20 mg/ml, Sigma), selenium selenite (50 μmol, Sigma), ethanolamine (50 μmol Sigma). The final ratio of medium to inoculated cells is 1×10 6  total cells per 1 ml of medium. The initiation of culture can be performed in 2 alternative ways:
       a) inoculation of nucleated cells after red cell lysis in GTI-medium   b) inoculation of separated CD34+ cells (or alternatively CD133+ cells) together with separated CD14+ cells as supplement in GTI-medium at a ratio of 1 cell CD34+ [or alternatively CD133+ cells] : 1cell CD14+)   c) inoculation of separated CD34+ cells (or alternatively CD133+ cells) in GTI-medium       
 
         [0058]    Cells are cultivated in the aforementioned medium and ratios under appropriate conditions. Appropriate conditions exemplary with regard to adequate culture containers, temperature, relative humidity, O 2  and CO 2  content of the gas phase are known to the expert. Preferentially the cells are cultivated in the aforementioned medium under the following conditions: (a) 37° C., (b) 100% relative humidity, (c) 10% O 2  and (d) 5% to 7% CO 2 . 
       2. Differentiation Decision at Day 3 In Vitro: 
       [0059]    At day 3 of culture the first medium supplementation is performed. At this point the cellular suspension culture is driven into either NK-cell differentiation or vascular progenitor (VP)-differentiation. 
         [0060]    This can be done in 2 ways:
       a) The entire product is further differentiated in only one of the two differentiation pathways (either NK- or VPC-differentiation)   b) The product is divided as required and one aliquot is further differentiated into NK-progenitors, the other one into VPC-progenitors.   c) Adherent cells are differentiated into VPC, non-adherent cells are further differentiated into NK-progenitors.       
 
       2.1. Generation of Natural Killer Cell Progenitor Product 
       [0064]    The designated amount of the initial cell culture product are supplemented at day 3 after initiation of culture with {umlaut over (G)}lycostem-{umlaut over (T)}echnology-{umlaut over (N)}{umlaut over (k)}-{umlaut over (d)}ay{umlaut over (3)} (GTNKd3)-medium (1 ml GTNKd3-medium per 1×10 6  total input cells). At day 6 the suspension culture is supplemented with {umlaut over (G)}lycostem-{umlaut over (T)}echnology-{umlaut over (N)}{umlaut over (k)}-{umlaut over (d)}ay{umlaut over (6)} (GTNKd6)-medium (2 ml GTNKd6-medium per 1×10 6  total input cells). From day 9 after initiation of culture the medium supplementation occurs the following way:
       Day 9: addition of 4 ml GTNKd6-medium per 1×10 6  total input cells   Day 12: addition of 8 ml GTNKd6-medium per 1×10 6  total input cells   Day 15: addition of 16 ml GTNKd6-medium per 1×10 6  total input cells       
 
         [0068]    At day 18-21 all cells are harvested and 2 washing steps in PBS containing 1% human AB-serum are performed according to standard operating procedures known to the person skilled in the field. Afterwards cells are resuspended in physiological NaCl-solution (0,9%) for infusion into the patient. After infusion, the NK-IC-progenitors, specifically generated to maturate within the patients body (in vivo) and finally differentiate in vivo into functional Natural Killer cells, that are able to kill specific tumor cell targets. For this reason the patient is preferably treated immediately after infusion with subcutaneous IL-2 (Proleukin©) at a dose of 2×10 6  IU/kg body weight. 
         [0069]    A small aliquot (200 cells total) is used for quality assurance control of the product to enumerate the number of NK-cell progenitors in the final product using the well established NK-IC assay as described in the literature (Miller et al., 1999; Punzel et al., 1999). 
         [0070]    Experimental example: In 3 independent UCB-samples (amount between 26-59 ml; TNC [total nucleated cells] ranging from 2-6×10 8 ) NK-IC progenitors could be generated with a total cell count between 1,1-1,9×10 8 . Since 1 single NK-IC generates &gt;1000 mature NK-cells in vivo, a minimum of 10 packages each with the capacity to generate 1×10 8 /kg body weight mature NK-cells can be cryopreserved until use according to standard operating procedures known to the expert in the field. 
       Media: 
       [0071]    GTNKd 3-medium 
         [0072]    The medium consists of DMEM/Ham&#39;s 12-Medium (Invitrogen Inc.) volume-ratio 2:1 (V/V) with 8% human AB-serum (Cambrex Inc.), O-acetyl-L-carnitine (OALC, Sigma Chemicals) or derivatives in a final concentration of 5 mmol/l, N-desulfated-N-acetylated heparin (Seigagaku Amerika Inc.) in a concentration of 60 mg/l. The following recombinant human cytokines (if not specifically mentioned all cytokines have been provided by Stem Cell Technology Inc. or R&amp;D Systems): thrombopoietin (TPO; 25 ng/ml); flt-3Ligand (FLT-3L; 25 ng/ml), stem cell factor (SCF; 25 ng/ml), interleukin-7 (IL-7; 25 ng/ml), vascular endothelial growth factor (VEGF; 10 ng/ml), interleukin-2 (Proleukin© [Chiron]; 750 U/ml), granulocyte-macrophage-colony-stimulating factor (GM-CSF; 10 pg/ml Immunex Corp., Seattle, Wash.), granulocyte-colony-stimulating factor (G-CSF, 250 pg/ml; Amgen, Thousand Oaks, Calif.), Leukemia-inhibitory factor (LIF; 50 pg/ml), Macrophage-inflammatory protein-1alpha (200 pg/ml; MIP-I alpha) and interleukin-6 (IL-6; 50 pg/ml). Additional supplements are L-glutamine (2 mmol/l; Invitrogen), penicillin (1000 U/ml), streptomycin 100 U/ml (Invitrogen), 25 μM 2-mercaptoethanol-beta (Invitrogen) ascorbic acid (20 mg/ml, Sigma), selenium selenite (50 μmol, Sigma), ethanolamine (50 μmol Sigma). 
         [0000]    GTNKd 6-medium 
         [0073]    The medium consists of DMEM/Ham&#39;s 12-Medium (Invitrogen Inc.) volume-ratio 2:1 (V/V) with 8% human AB-serum (Cambrex Inc.), O-acetyl-L-carnitine (OALC, Sigma Chemicals) or derivatives in a final concentration of 5 mmol/l, N-desulfated-N-acetylated heparin (Seigagaku Amerika Inc.) in a concentration of 60 mg/l. The following recombinant human cytokines (if not specifically mentioned all cytokines have been provided by Stem Cell Technology Inc. or R&amp;D Systems): thrombopoietin (TPO; 25 ng/ml); flt-3Ligand (FLT-3L; 25 ng/ml), stem cell factor (SCF; 25 ng/ml), interleukin-7 (IL-7; 25 ng/ml), interleukin-15 (IL-15; 25 ng/ml), interleukin-2 (Proleukin© [Chiron]; 1500 U/ml), granulocyte-macrophage-colony-stimulating factor (GM-CSF; 10 pg/ml Immunex Corp., Seattle, Wash.), granulocyte-colony-stimulating factor (G-CSF, 250 pg/ml; Amgen, Thousand Oaks, Calif.), Leukaemia-inhibitory factor (LIF; 50 pg/ml), Macrophage-inflammatory protein-1alpha (200 pg/ml; MIP-I alpha) and interleukin-6 (IL-6; 50 pg/ml). Additional supplements are L-glutamine (2 mmol/l; Invitrogen), penicillin (1000 U/ml), streptomycin 100 U/ml (Invitrogen), 25 μM 2-mercaptoethanol-beta (Invitrogen) ascorbic acid (20 mg/ml, Sigma), selenium selenite (50 μmol, Sigma), ethanolamine (50 μmol Sigma). 
         [0074]    NK-IC-assay for quality control: This assay enumerates the number of primitive NK-cell-progenitors that have been generated at day 18 of culture. Each single NK-IC progenitor can give rise to &gt;1000 mature and functional NK-cells. Thus, this assay provides a valuable readout and quality control instrument for the product. The small aliquot of expanded cells (200 cells) will be plated into 96 well plates in limiting dilution assays in AFT024-cocultures supplemented with medium that consist of DMEM/Ham&#39;s 12-Medium 2:1 (V/V) with 20% human heat-inactivated AB-Serum and 20 mg/ml ascorbic acid, 50 μmol selenium selenite, 25 μmol 13-mercaptoethanol, 50 μmol ethanolamine, 1000 U/ml IL-2, 5 ng/ml IL-3 [only initially], 10 ng/ml Flt-3L, 10 ng/ml SCF und 20 ng/ml IL-7. After 5-7 weeks of culture cells were analysed phenotypically for mature and functional NK-cells (CD56+/CD3−/CD16/NKp30/NKp44/NKp46,NKG2A/CD94, CD107). 
         [0075]    2.2. Generation of Vascular Progenitor Cell Products 
         [0076]    The designated amount of the initial cell culture product has to be placed on fibronectin coated tissue culture treated 175 cm 2  flasks at day 3 after initiation and needs to be supplemented further with  G lycostem- T echnology- V ascular- P rogenitor  d ay  3 -medium (GTVPd3)-medium (15 ml GTVPd3-medium per 175 cm 2  flasks). At day 6 all non-adherent cells have to be removed and medium supplementation has to occur from day 6 the following way: 
         [0077]    Day 6: exchange of 15 ml GTVPd6-medium per flask 
         [0078]    Day 12: exchange of 15 ml GTVPd6-medium per flask 
         [0079]    Day 18: exchange of 15 ml GTVPd6-medium per flask 
         [0080]    Day 24: exchange of 15 ml GTVPd6-medium per flask 
         [0081]    At day 18-28 all cells are harvested using cell dissociation solution (Becton-Dickinson) and 2 washing steps in PBS containing 1% human AB-serum are performed according to standard operating procedures known to the expert in the field. Afterwards cells are resuspended in physiological NaCl-solution (0,9%) for infusion into the patient 
         [0082]    A small aliquot (1000 cells total) is used for quality assurance control of the product to enumerate the number of VP-cell progenitors in the final product using well established Vascular Progenitor cell detection methods that are well known to the person of skill in the field. Phenotypic verification of endothelial progenitor cells has to include CD31, vWF, and DiL-uptake as it is well known to the skilled person in the field. Several publications for the detection of VP-cells have been published in the literature (Gehling et al., 2000; Loges et al., 2004). 
         [0000]    Experimental example: In 1 UCB-samples (amount 39 ml; TNC 2,2×10 8 ; CD34+0,9×10 6 ) VP-cell-colonies as defined are generated with a total cell count after harvest between 1,1-1,9×10 6 . cells. These cells are cryopreserved until use according to standard operating procedures known to the expert in the field. 
       Media: 
       [0083]    GTVPd3-medium 
         [0084]    The medium consists of M199 basal medium supplemented with 10% human AB-serum (Cambrex Inc.), O-acetyl-L-carnitine (OALC, Sigma Chemicals) or derivatives in a final concentration of 5 mmol/l, The following recombinant human cytokines (if not specifically mentioned all cytokines have been provided by Stem Cell Technology Inc. or R&amp;D Systems): Stem cell growth factor (50 ng, SCGF) vascular endothelial growth factor (VEGF; 50 ng/ml), angiopoietin-1 (10 ng, R&amp;D-systems), angiopoietin-2 (10 ng, R&amp;D-systems), basic fibroblast growth factor (bFGF; 10 ng/ml), insulin like growth factor (IGF; 10 ng/ml), thrombopoietin (TPO; 25 ng/ml); flt-3Ligand (FLT-3L; 25 ng/ml), interleukin-113 (IL-1, 20 ng/ml), granulocyte-macrophage-colony-stimulating factor (GM-CSF; 10 pg/ml Immunex Corp., Seattle, Wash.), granulocyte-colony-stimulating factor (G-CSF, 250 pg/ml; Amgen, Thousand Oaks, Calif.), Leukemia-inhibitory factor (LIF; 50 pg/ml), Macrophage-inflammatory protein-1alpha (200 pg/ml; MIP-I alpha) and interleukin-6 (IL-6; 50 pg/ml). Additional supplements are L-glutamine (2 mmol/l; Invitrogen), penicillin (1000 U/ml), streptomycin (100 U/ml, Invitrogen), 25 μM 2-mercaptoethanol-beta (Invitrogen) ascorbic acid (20 mg/ml, Sigma). 
         [0000]    GTVPd 6-medium 
         [0085]    The medium consists of M199 basal medium supplemented with 2% human AB-serum (Cambrex Inc.), O-acetyl-L-carnitine (OALC, Sigma Chemicals) or derivatives in a final concentration of 5 mmol/l, The following recombinant human cytokines (if not specifically mentioned all cytokines have been provided by Stem Cell Technology Inc. or R&amp;D Systems): Stem cell growth factor (50 ng, SCGF) vascular endothelial growth factor (VEGF; 50 ng/ml), basic fibroblast growth factor (bFGF; 10 ng/ml), insulin like growth factor (IGF; 10 ng/ml), thrombopoietin (TPO; 25 ng/ml); flt-3Ligand (FLT-3L; 25 ng/ml), interleukin-113 (IL-1, 20 ng/ml). Additional supplements are L-glutamine (2 mmol/l; Invitrogen), penicillin (1000 U/ml), streptomycin (100 U/ml, Invitrogen), 25 μM 2-mercaptoethanol-beta (Invitrogen) ascorbic acid (20 mg/ml, Sigma). 
       REFERENCES 
       [0086]    Gehling, U. M., Ergun, S., Schumacher, U., Wagener, C., Pantel, K., Otte, M., Schuch, G., Schafhausen, P., Mende, T., Kilic, N., et al. (2000). In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95, 3106-3112. 
         [0087]    Loges, S., Fehse, B., Brockmann, M. A., Lamszus, K., Butzal, M., Guckenbiehl, M., Schuch, G., Ergun, S., Fischer, U., Zander, A. R., et al. (2004). Identification of the adult human hemangioblast. Stem Cells Dev 13, 229-242. 
         [0088]    Miller, J. S., McCullar, V., Punzel, M., Lemischka, I. R., and Moore, K. A. (1999). Single adult human CD34(+)/Lin-/CD38(−) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells. Blood 93, 96-106. 
         [0089]    Punzel, M., Wissink, S. D., Miller, J. S., Moore, K. A., Lemischka, I. R., and Verfaillie, C. M. (1999). The myeloid-lymphoid initiating cell (ML-IC) assay assesses the fate of multipotent human progenitors in vitro. Blood 93, 3750-3756.